Regeneron Pharmaceuticals Inc (REGN): Sanofi , 10% owner of Regeneron Pharmaceuticals Inc purchased 64,731 shares on Jun 14, 2016. The Insider buying transaction was reported by the company on Jun 16, 2016 to the Securities and Exchange Commission. The shares were purchased at $364.22 per share for a total value of $23552858 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 25, 2016, Arthur F Ryan (director) sold 1,000 shares at $396.64 per share price.On May 19, 2016, Plew Daniel P Van (EVP & General Mgr Industrial O) sold 4,413 shares at $385.77 per share price.Also, On Apr 7, 2016, Joseph L Goldstein (director) sold 2,000 shares at $425.00 per share price.On Jan 14, 2016, Sanofi (10% owner) purchased 83,938 shares at $463.51 per share price.
Regeneron Pharmaceuticals Inc: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in Regeneron Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $368.71 and hit $376.3192 on the upside , eventually ending the session at $367.91, with a gain of 0.39% or 1.42 points. The heightened volatility saw the trading volume jump to 6,75,048 shares. The 52-week high of the share price is $605.9299 and the company has a market cap of $38,659 M . The 52-week low of the share price is at $348.96.
Company has been under the radar of several Street Analysts.Regeneron Pharmaceuticals Inc is Downgraded by Wells Fargo to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Apr 20, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.